Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019 [PDF]
, 2022 Qian Gao +7 more
openalex +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source
AB0477 Inhibition of large joint destruction in rheumatoid arthritis patients treated with tocilizumab [PDF]
, 2018 Y. Hirano +2 more
openalex +1 more source
The role of cytokines in ovarian cancer drug resistance
International Journal of Cancer, Volume 158, Issue 4, Page 821-834, 15 February 2026.Abstract Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients
Lu Wang +7 more
wiley +1 more source
Serum Biomarkers and Musculoskeletal Ultrasound for Assessment of Disease Activity in Patients With Juvenile Idiopathic Arthritis During Tocilizumab Therapy [PDF]
Ehsan Khalifa Elsayed +4 more
openalex +1 more source
Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates [PDF]
, 2022 Laetitia Diep +8 more
openalex +1 more source
NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-Adjustment [PDF]
, 2011 Ades, A E +3 more
core +2 more sources